In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants

  • Antimicrob Agents Chemother. 2007 Jun;51(6):2240-3. doi: 10.1128/AAC.01440-06.
M N Brunelle  1 ,  J Lucifora ,  J Neyts ,  S Villet ,  A Holy ,  C Trepo ,  F Zoulim
Affiliations
  • 1. INSERM, U871, 151 Cours Albert Thomas, 69424 Lyon cedex 03, France.
PMID: 17371827 DOI: 10.1128/AAC.01440-06
Abstract

The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV Infection.